Posibles tratamientos farmacológicos en estudio para pacientes sintomáticos de COVID-19: Una revisión integradora
DOI:
https://doi.org/10.33448/rsd-v10i6.15579Palabras clave:
Posibles tratamientos; COVID-19; Pandemia; Nuevo coronavirus; SARS-CoV-2.Resumen
Objetivo: Realizar una revisión integradora de los posibles tratamientos farmacológicos que se están estudiando actualmente como estratégias terapéuticas para los pacientes COVID-19 positivos. Métodos: Se realizó una revisión integradora de estudios de la base de datos del Medical Literature Analysis and Retrieval System, mediante el sistema de búsqueda PUBMED, en la que se seleccionaron 58 artículos que abarcan 9 clases de fármacos. Resultados: La distribución de los 58 artículos incluidos en la revisión se categorizó por fármaco abordado. Se consideraron tratamientos con mejoría significativa aquellos que observaron una reducción de la carga viral, una reducción del tempo de hospitalización o mejoría clínica estadísticamente relevante según los criterios de cada estudio. Conclusión: Ante la urgencia de producir resultados rápidos, se observó que existe una gran dificultad en la realización de ensayos clínicos ciegos, doble ciego, haciendo con que la comunidad científica se restrinja principalmente a estudios retrospectivos y observacionales, los cuales no son tan eficientes como el anteriormente mencionado. Con base en la observación de los estudios, aún no existe un tratamiento efectivo para COVID-19, y la aplicación de medidas preventivas es crucial para evitar el impacto de la enfermedad en la población.
Citas
Ahn, D.-G., Shin, H.-J., Kim, M.-H., Lee, S., Kim, H.-S., Myoung, J., Kim, B.-T., & Kim, S.-J. (2020) Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19). Journal Of Microbiology and Biotechnology, 30 (3), 313-324. doi: http://dx.doi.org/10.4014/jmb.2003.03011.
Antinori, S., Cossu, M. V., Ridolfo, A. L., Rech, R., Bonazzetti, C., Pagani, G., . . . Castelli, A. (2020). Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: clinical outcome and differences in post-treatment hospitalisation status. Pharmacological Research, (158), 1-6. doi: http://dx.doi.org/10.1016/j.phrs.2020.104899.
Arshad, S., Kilgore, P., Chaudhry, Z. S., Jacobsen, G., Wang, D. D., Huitsing, K., . . . Mckinnon, J. E. (2020). Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. International Journal of Infectious Diseases, (97), 396-403. doi: http://dx.doi.org/10.1016/j.ijid.2020.06.099.
Asakura, H., & Ogawa, H. (2021). COVID-19-associated coagulopathy and disseminated intravascular coagulation. International journal of hematology, 113(1), 45–57. doi: https://doi.org/10.1007/s12185-020-03029-y
Ayerbe, L., Risco, C., & Ayis, S. (2020). The association between treatment with heparin and survival in patients with Covid-19. Journal Of Thrombosis and Thrombolysis, 50 (2), 298-301. doi: http://dx.doi.org/10.1007/s11239-020-02162-z.
Bai, Y., Yao, L., Wei, T., Tian, F., Jin, D.-Y., Chen, L., & Wang, M. (2020) Presumed Asymptomatic Carrier Transmission of COVID-19. Jama, 323 (14), 1406-1407. doi: http://dx.doi.org/10.1001/jama.2020.2565.
Bani-Sadr, F., Hentzien, M., Pascard, M., N'guyen, Y., Servettaz, A., Andreoletti, L, Kanagaratnam, L., & Jolly, D. (2020). Corticosteroid therapy for patients with COVID-19 pneumonia: a before⠳after study. International Journal of Antimicrobial Agents, 56(2), 1-4. doi: http://dx.doi.org/10.1016/j.ijantimicag.2020.106077.
Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., . . . Kline, S. (2020). Remdesivir for the Treatment of Covid-19 — Final Report. New England Journal of Medicine, 383 (19), 1813-1826. doi: http://dx.doi.org/10.1016/j.ijantimicag.2020.106077.
Campochiaro, C., Della-Torre, E., Cavalli, G., Luca, G., Ripa, M., Boffini, N., . . . Ruggeri, A. (2020). Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. European Journal of Internal Medicine, 76 (1), 43-49. doi: http://dx.doi.org/10.1016/j.ejim.2020.05.021.
Cao, Y., Wei, J., Zou, L., Jiang, T., Wang, G., Chen, L., . . . Wang, N. (2020). Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. Journal Of Allergy and Clinical Immunology, 146 (1), 137-146. doi: http://dx.doi.org/10.1016/j.jaci.2020.05.019.
Capochiani, E.; Frediani, B.; Iervasi, G.; Paolicchi, A.; Sani, S.; Roncucci, P., . . . Carrara, D. (2020). Ruxolitinib Rapidly Reduces Acute Respiratory Distress Syndrome in COVID-19 Disease. Analysis of Data Collection from RESPIRE Protocol. Frontiers In Medicine, 7, (1), 1-9. doi: http://dx.doi.org/10.1016/j.jaci.2020.05.019.
Catteau, L., Dauby, N., Montourcy, M., Bottieau, E., Hautekiet, J., Goetghebeur, E., . . . Wyndham-Thomas, C. (2020). Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants. International Journal of Antimicrobial Agents, 56 (4), 106144-106153. doi: http://dx.doi.org/10.1016/j.ijantimicag.2020.106144.
Chan, J. F.-W., Yuan, S., Kok, K.-H, To, K. K.-W., Chu, H., Yang, J., . . . Poon, R. W. S. (2020). A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. The Lancet, 395 (10223), 514-523. doi: http://dx.doi.org/10.1016/s0140-6736(20)30154-9.
Conrozier, T., Lohse, A., Balblanc, J. C., Dussert, P., Royer, P. Y., Bossert, M., . . . Zayet, S. (2020). Biomarker variation in patients successfully treated with tocilizumab for severe coronavirus disease 2019 (COVID-19): results of a multidisciplinary collaboration. Clinical And Experimental Rheumatology, 4 (38) 742-747.
Dastan, F., Nadji, S. A., Saffaei, A., Marjani, M., Moniri, A., Jamaati, H., . . . Varahram, M. (2020). Subcutaneous administration of interferon beta-1a for COVID-19: a non-controlled prospective trial. International Immunopharmacology, 85, 1-5. doi: http://dx.doi.org/10.1016/s0140-6736(20)30154-9.
Davoudi-Monfared, E., Rahmani, H., Khalili, H., Hajiabdolbaghi, M., Salehi, M., Abbasian, L., Kazemzadeh, H., & Yekaninejad, M. S. (2020). A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19. Antimicrobial Agents and Chemotherapy, 64 (9), 1-14. doi: http://dx.doi.org/10.1128/aac.01061-20.
Dehelean, C. A., Lazureanu, V., Coricovac, D., Mioc, M., Oancea, R., Marcovici, I., . . . Cretu, O. (2020). SARS-CoV-2: repurposed drugs and novel therapeutic approaches⠴insights into chemical structure⠴biological activity and toxicological screening. Journal Of Clinical Medicine, 9 (7), 2084-2094. doi: http://dx.doi.org/10.3390/jcm9072084.
Esakandari, H., Nabi-Afjadi, M., Fakkari-Afjadi, J., Farahmandian, N., Miresmaeili, S. M. &, Bahreini, E. (2020). A comprehensive review of COVID-19 characteristics. Biological Procedures Online, 22 (1), 1-10. doi: http://dx.doi.org/10.3390/jcm9072084.
Eslami, G., Mousaviasl, S., Radmanesh, E., Jelvay, S., Bitaraf, S., Simmons, B., . . . Freeman, J. (2020). The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19. Journal Of Antimicrobial Chemotherapy, 75 (11), 3366-3372. doi: http://dx.doi.org/10.3390/jcm9072084.
Esposito, S., Noviello, S., & Pagliano, P. (2020). Update on treatment of COVID-19: ongoing studies between promising and disappointing results. Infezmed, 2 (28), 198-211.
Fehr, A. R., & Perlman, S. (2015). Coronaviruses: an overview of their replication and pathogenesis. Coronaviruses, 1-23. doi: http://dx.doi.org/10.3390/jcm9072084.
Gao, G., Wang, A., Wang, S., Qian, F., Chen, M., Yu, F., . . . Zhao, T. (2020). A retrospective evaluation on the efficacy of Lopinavir/ritonavir and chloroquine to treat non-severe COVID-19 patients. Jaids Journal of Acquired Immune Deficiency Syndromes, 239-243. doi: http://dx.doi.org/10.1097/qai.0000000000002452.
Gautret, P., Lagier, J.C., Parola, P., Hoang, V. T., Meddeb, L., Sevestre, J., . . . Amrane, S. (2020). Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study. Travel Medicine And Infectious Disease, 34, 101663-101673. doi: http://dx.doi.org/10.1097/qai.0000000000002452.
Gautret, P, Lagier, J. C. J, Parola, P., Hoang, V. T., Meddeb, L., Mailhe, M., . . . Vieira, V. E. (2020). Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International Journal Of Antimicrobial Agents, 56 (1), 105949-105963. doi: http://dx.doi.org/10.1097/qai.0000000000002452.
Geleris, J., Sun, Y., Platt, J., Zucker, J., Baldwin, M., Hripcsak, G., . . . Barr, R. G. (2020). Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. New England Journal of Medicine, 382 (25), 2411-2418. doi: http://dx.doi.org/10.1056/nejmoa2012410.
Giudice, V., Pagliano, P., Vatrella, A., Masullo, A., Poto, S., Polverino, B. M., . . .Vitale, C. (2020). Combination of Ruxolitinib and Eculizumab for Treatment of Severe SARS-CoV-2-Related Acute Respiratory Distress Syndrome: a controlled study. Frontiers In Pharmacology, 11, (1), 1-6. doi: http://dx.doi.org/10.3389/fphar.2020.00857.
Goldman, J. D., Lye, D. C. B., Hui, D. S. Marks, K. M.; Bruno, R., Montejano, R., . . . Nahass, R. G. (2020). Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. New England Journal Of Medicine, 383 (19), 1827-1837. doi: https://doi.org/10.1056/NEJMoa2015301.
Guo, Y.-R., Cao, Q.-D., Hong, Z.-S., Tan, Y.-Y., Chen, S.-D., Jin, H.-J., . . .Yan, Y. (2020). The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Military Medical Research, 7 (1) 1-10. doi: https://doi.org/10.1186/s40779-020-00240-0.
Hao, S.-R., Yan, R., Zhang, S.-Y., Lian, J.-S., Cai, H., Zhang, X.-L., . . . Yu, G.-D. (2020). Interferon-α2b spray inhalation did not shorten virus shedding time of SARS-CoV-2 in hospitalized patients: a preliminary matched case-control study. Journal Of Zhejiang University-Science B, 21 (8), 628-636. doi: https://doi.org/10.1631/jzus.B2000211.
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., . . . Gu, X. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet, 395 (10223), 497-506. doi: https://doi.org/10.1016/S0140-6736(20)30183-5.
Huang, M., Tang, T., Pang, P., Li, M., Ma, R., Lu, J., . . . Liang, J. (2020). Treating COVID-19 with Chloroquine. Journal Of Molecular Cell Biology, 12 (4) 322-325. doi: https://doi.org/10.1093/jmcb/mjaa014.
Hung, I. F.-N., Lung, K.-C., Tso, E. Y.-K., Liu, R., Chung, T. W.-H., Chu, M.-Y., . . . Tam, A. R. (2020). Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. The Lancet, 395 (10238), 1695-1704. doi: https://doi.org/10.1016/S0140-6736(20)31042-4.
Ip, A., Berry, D. A., Hansen, E., Goy, A. H., Pecora, A. L., Sinclaire, B. A., . . . Berry, N. S. (2020). Hydroxychloroquine and tocilizumab therapy in COVID-19 patients—An observational study. Plos One, 15 (8), 1-19. doi: https://doi.org/10.1371/journal.pone.0237693
Kasgari, H. A., Moradi, S., Shabani, A. M., Babamahmoodi, F., Badabi, A. R. D., Davoudi, L., . . . Merat, S. (2020). Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial. Journal Of Antimicrobial Chemotherapy, 75 (11), 3373-3378. doi: https://doi.org/10.1093/jac/dkaa332.
Kashour, Z., Riaz, M., Garbati, M., Aldosary, O., Tlayjeh, H., Gerberi, D., Murad, M. H., . . . Imad; M. (2020). Efficacy of chloroquine or hydroxychloroquine in COVID-19 patients: a systematic review and meta-analysis. Journal Of Antimicrobial Chemotherapy, 1 (1), 1-13. doi: https://doi.org/10.1093/jac/dkaa403.
Klopfenstein, T., Zayet, S., Lohse, A., Balblanc, J. C., Badie, J., Royer, P. Y., . . . Bossert, M. (2020). Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients. Médecine Et Maladies Infectieuses, 50 (5) 397-400. Doi: https://doi.org/10.1016/j.medmal.2020.05.001.
Lam, S., Lombardi, A., & Ouanounou, A. (2020). COVID-19: a review of the proposed pharmacological treatments. European Journal of Pharmacology, 886 (1), 1-10. doi: https://doi.org/10.1016/j.ejphar.2020.173451.
Lan, S.-H., Lai, C.-C, Huang, H.-T., Chang, S.-T., Lu, L.-C., & Hsueh, P.-R. (2020). Tocilizumab for severe COVID-19: a systematic review and meta-analysis. International Journal of Antimicrobial Agents, 56 (3), 106103-10615. doi: https://doi.org/10.1016/j.ijantimicag.2020.106103.
Lecronier, M., Beurton, A., Burrel, S., Haudebourg, L., Deleris, R.., Marec, J. L., . . . Mora, P. (2020). Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis. Critical Care, 24 (1), 1-9. doi: https://doi.org/10.1186/s13054-020-03117-9.
Letko, M., Marzi, A., & Munster, V. (2020). Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nature Microbiology, 5 (4), 562-569. doi: https://doi.org/10.1038/s41564-020-0688-y.
Levy, C., Lassailly, G., Parmentier, E., Duburcq, T., Mathurin, P., & Poissy, J. (2020). Caution With the Use of Lopinavir/Ritonavir in Severely Ill Patients for the Treatment of SARS-CoV-2: a report of severe jaundice. American Journal Of Gastroenterology, 115 (10), 1716-1718. doi: https://doi.org/10.14309/ajg.0000000000000828.
Li, W., Shi, Z., Yu, M., Ren, W., Smith, C., Epstein, J. H., Wangd, H., & Crameri, Gary. (2005). Bats Are Natural Reservoirs of SARS-Like Coronaviruses. Science, 310 (5748) 676-679. doi: https://doi.org/10.1126/science.1118391.
Li, Y., Zhou, X., Li, T.; Chan, S., Yu, Y., Ai, J.-W., . . . Zhu, L. Corticosteroid prevents COVID-19 progression within its therapeutic window: a multicentre, proof-of-concept, observational study. Emerging Microbes & Infections, 9, (1) 1869-1877. doi: https://doi.org/10.1080/22221751.2020.1807885.
Lovato, A., Filippis, C., & Marioni, G. (2020). Upper airway symptoms in coronavirus disease 2019 (COVID-19). American Journal Of Otolaryngology, 41 (3) 102474-102486. doi: https://doi.org/10.1016/j.amjoto.2020.102474.
Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., . . . Zhu, N. (2020). Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The Lancet, 395 (10224), 565-574. doi: https://doi.org/10.1016/s0140-6736(20)30251-8.
Luo, P., Liu, Y., Qiu, L., Liu, X., Liu, D., & Li, J. (2020). Tocilizumab treatment in COVID‐19: a single center experience. Journal Of Medical Virology, 92 (7), 814-818. doi: https://doi.org/10.1002/jmv.2580.
Mahévas, M., Tran, V. T., Roumier, M., Chabrol, A., Paule, R., Guillaud, C., . . . Lescure, F. X. (2020). Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. Bmj, 1844-1856. doi: https://doi.org/10.1136/bmj.m1844.
Majmundar, M., Kansara, T., Lenik, J. M., Park, H., Ghosh, K., Doshi, R., . . . Chaudhari, S. (2020). Efficacy of corticosteroids in non-intensive care unit patients with COVID-19 pneumonia from the New York Metropolitan region. Plos One, 15 (9) 1-14. doi: https://doi.org/10.1371/journal.pone.0238827.
Mikulska, M., Nicolini, L. A., Signori, A., Biagio, A., Sepulcri, C., Russo, C., . . . Giacobbe, D. R. (2020). Tocilizumab and steroid treatment in patients with COVID-19 pneumonia. Plos One, 15, (8) 1-16. doi: https://doi.org/10.1371/journal.pone.0237831.
Million, M., Lagier, J. C., Gautret, P., Colson, P., Fournier, P. E., Amrane, S., . . . Doudier, B. (2020). Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: a retrospective analysis of 1061 cases in marseille, france. Travel Medicine And Infectious Disease, 35, 101738-101747. doi: https://doi.org/10.1016/j.tmaid.2020.101738.
Morena, V., Milazzo, L., Oreni, L., Bestetti, G., Fossali, T., Bassoli, C., . . . Ballone, E. (2020). Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy. European Journal Of Internal Medicine 76, 36-42. doi: https://doi.org/10.1016/j.ejim.2020.05.011.
Mulangu, S., Dodd, L. E., Davey, R. T., Mbaya, O. T., Proschan, M., Mukadi, D., . . . Ibanda, A. (2019). A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. New England Journal Of Medicine, 381 (24), 2293-2303. doi: https://doi.org/10.1056/NEJMoa1910993.
Nittari, G., Pallotta, G., Amenta, F., & Tayebati, S. K. (2020). Current pharmacological treatments for SARS-COV-2: a narrative review. European Journal of Pharmacology, 882, 173328-173339. doi: https://doi.org/10.1016/j.ejphar.2020.173328.
Ren, L.-L., Wang, Y.-M., Wu, Z.-Q., Xiang, Z.-C., Guo, L., Xu, T., . . . Li, X.-W. (2020). Identification of a novel coronavirus causing severe pneumonia in human. Chinese Medical Journal, 133 (9), 1015-1024. doi: https://doi.org/10.1097/CM9.0000000000000722
Rizk, J. G., Kalantar-Zadeh, K., Mehra, M. R.., Lavie, C. J., Rizk, Y., & Forthal, D. N. (2020). Pharmaco-Immunomodulatory Therapy in COVID-19. Drugs, 80, (13) 1267-1292. doi: https://doi.org/10.1007/s40265-020-01367-z
Rojas-Marte, G., Khalid, M., Mukhtar, O., Hashmi, A. T., Waheed, M., Ehrlich, S., . . . Malyshev, Y. (2020). Outcomes in patients with severe COVID-19 disease treated with tocilizumab: a case controlled study. Qjm: An International Journal of Medicine, 113 (8) 546-550. doi: https://doi.org/10.1093/qjmed/hcaa206
Sanders, J. M., Monogue, M. L., Jodlowski, T. Z., & Cutrell, J. B. (2020). Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA, 323(18), 1824–1836. doi: https://doi.org/10.1001/jama.2020.6019
Satlin, M. J., Goyal, P., Magleby, R., Maldarelli, G. A., Pham, K., Kondo, M., . . . Choi, J. J. (2020). Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease. Plos One, 15, (7) 1-14. doi: https://doi.org/10.1371/journal.pone.0236778
Schrezenmeier, E., & Dörner, T. (2020). Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nature Reviews Rheumatology, 16 (3), 155-166. doi: https://doi.org/10.1038/s41584-020-0372-x.
Sciascia, S., Aprà, F., Baffa, A., Baldovino, S., Boaro, D., Boero, R., . . . Rossi, D. (2020). Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. Clinical And Experimental Rheumatology, 38, (3), 529-532.
Tang, W.; Cao, Z.; Han, M.; Wang, Z.; Chen, J.; Sun, W.; Wu, Y.; Xiao, W.; Liu, S. & Chen, E. (2020). Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. Bmj, 1849 (369), 1-11. doi: https://doi.org/10.1136/bmj.m1849.
Tong, S., Su, Y., Yu, Y., Wu, C., Chen, J., Wang, S., & Jiang, J. (2020). Ribavirin therapy for severe COVID-19: a retrospective cohort study. International Journal Of Antimicrobial Agents, 56 (3) 1-13. doi: https://doi.org/10.1016/j.ijantimicag.2020.106114.
Toniati, P., Piva, S., Cattalini, M., Garrafa, E., Regola, F., Castelli F., . . . Beindorf, E. A. (2020). Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in brescia, italy. Autoimmunity Reviews, 19 (7) 1-6. doi: https://doi.org/10.1016/j.autrev.2020.102568.
Tortorici, M. A., & Veesler, D. (2019). Structural insights into coronavirus entry. Advances In Virus Research, p. 93-116. doi: https://doi.org/10.1016/bs.aivir.2019.08.002.
Vijayvargiya, P., Garrigos, Z. E., Almeida, N. E. C., Gurram, P. R., Stevens, R. W., & Razonable, R. R. (2020). Treatment Considerations for COVID-19. Mayo Clinic Proceedings, 95 (7), 1454-1466. doi: https://doi.org/10.1016/j.mayocp.2020.04.027.
Vincent, M. J., Bergeron, E., Benjannet, S, Erickson, B. R, Rollin, P., Ksiazek, T. G., Seidah, N. G., & Nichol, S. T. (2005). Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virology Journal, 69 (1), 1-10. doi: https://doi.org/10.1186/1743-422X-2-69.
Wan, S., Yi, Q., Fan, S., Lu., J., Zhang, X., Guo, L., . . . Yi, Z. (2020). Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). Medrxiv, 1-13. doi: https://doi.org/10.1101/2020.02.10.20021832.
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., . . . Xiong, Y. (2020). Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. Jama, 323 (11), 1061-1073. doi: https://doi.org/10.1001/jama.2020.1585.
Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., . . . Xiao, G. (2020). Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research, 30 (3), 269-271. doi: https://doi.org/10.1038/s41422-020-0282-0.
Wang, N., Zhan, Y., Zhu, L., Hou, Z., Liu, F., Song, P., . . . Wan, D. (2020). Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients. Cell Host & Microbe, 28 (3), 455-464. doi: https://doi.org/10.1016/j.chom.2020.07.005
World Health Organization. (2020a). WHO Coronavirus Disease (COVID-19) Dashboard. Recuperado de https://covid19.who.int/table
World Health Organization. (2020b). Clinical management of COVID-19. Recuperado de https://www.who.int/publications/i/item/clinical-management-of-covid-19.
World Health Organization. (2020c). WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. Recuperado de https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020
World Health Organization. (2020d). Therapeutics and COVID-19: living guideline. Recuperado de https://www.who.int/publications/i/item/therapeutics-and-covid-19-living-guideline.
Xu, P., Huang, J., Fan, Z., Huang, W., Qi, M., Lin, X., Song, W., & Yi, L. (2020). Arbidol/IFN-α2b therapy for patients with corona virus disease 2019: a retrospective multicenter cohort study. (2020). Microbes And Infection, 22 (4-5), 200-205. doi: http://dx.doi.org/10.1016/j.micinf.2020.05.012.
Xu, X., Han, M., Li, T., Sun, W., Wang, D., Fu, B., . . . Li, X. (2020). Effective treatment of severe COVID-19 patients with tocilizumab. Proceedings Of The National Academy Of Sciences, 117 (20), 10970-10975. doi: http://dx.doi.org/10.1073/pnas.2005615117.
Yan, D., Liu, X.-Y., Zhu, Y.-N., Huang, L., Dan, B.-T., Zhang, G.-J., & Gao, Y.-H. (2020). Factors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection. European Respiratory Journal, 56 (1), 1-9.doi: https://doi.org/10.1183/13993003.00799.
Yeleswaram, S., Smith, P., Burn, T., Covington, M., Juvekar, A., Li, Y., Squier, P., & Langmuir, P. (2020). Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment. Clinical Immunology, 218 (1) 108517-108526. doi: http://dx.doi.org/10.1016/j.clim.2020.108517.
Yousefi, B., Valizadeh, S., Ghaffari, H., Vahedi, A., Karbalaei, M., & Eslami, M. (2020). A global treatments for coronaviruses including COVID‐19. Journal Of Cellular Physiology, 235 (12), 9133-9142. doi: http://dx.doi.org/10.1002/jcp.29785.
Yuan, J., Zou, R., Zeng, L., Kou, S., Lan, J., Li, X., . . . Tang, S. (2020). The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients. Inflammation Research, 69 (6), 599-606. doi: http://dx.doi.org/10.1007/s00011-020-01342-0.
Yuen, K.-S., Ye, Z.-W., Fung, S.-Y., Chan, C.-P., & Jin, D.-Y. (2020). SARS-CoV-2 and COVID-19: the most important research questions. Cell & Bioscience, 10 (1), 1-5. doi: http://dx.doi.org/10.5694/mja2.50577.
Zha, L., Li, S., Pan, L., Tefsen, B., Li, Y., French, N., . . . Villanueva, E. V. (2020). Corticosteroid treatment of patients with coronavirus disease 2019 (COVID ‐19). Medical Journal Of Australia, 212 (9), 416-420. doi: http://dx.doi.org/10.5694/mja2.50577.
Zhang, W., Zhao, Y., Zhang, F., Wang, Q., Li, T., Liu, Z, . . . Yan, X. (2020). The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspectives of clinical immunologists from china. Clinical Immunology, 214, 108393-108404. doi: http://dx.doi.org/10.1016/j.clim.2020.108393.
Zhou, Q., Chen, V., Shannon, C. P., Wei, X.-S., Xiang, X., Wang, X., . . . Fish, E. N. (2020). Interferon-α2b Treatment for COVID-19. Frontiers In Immunology, 11, (1), 1-6. doi: http://dx.doi.org/10.3389/fimmu.2020.01061.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2021 Danielle Guimarães Silva; Renan Tripode Bartaquini; Beatriz Moraes Pedrosa; Carolina Heitmann Mares Azevedo Ribeiro; Ana Cristina Lo Prete
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Los autores que publican en esta revista concuerdan con los siguientes términos:
1) Los autores mantienen los derechos de autor y conceden a la revista el derecho de primera publicación, con el trabajo simultáneamente licenciado bajo la Licencia Creative Commons Attribution que permite el compartir el trabajo con reconocimiento de la autoría y publicación inicial en esta revista.
2) Los autores tienen autorización para asumir contratos adicionales por separado, para distribución no exclusiva de la versión del trabajo publicada en esta revista (por ejemplo, publicar en repositorio institucional o como capítulo de libro), con reconocimiento de autoría y publicación inicial en esta revista.
3) Los autores tienen permiso y son estimulados a publicar y distribuir su trabajo en línea (por ejemplo, en repositorios institucionales o en su página personal) a cualquier punto antes o durante el proceso editorial, ya que esto puede generar cambios productivos, así como aumentar el impacto y la cita del trabajo publicado.
